On the other hand, a study including 304 HER2-enriched metastatic breast cancer cases indicates that patients with AR+ tumors have a longer progression-free survival (PFS) and a higher 5-year overall survival (OS) rate than those with AR− tumors15. Here, ERBB2 is linked to breast carcinoma.